Pemvidutide
- Category
- Weight Management & Metabolic
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
A dual GLP-1/glucagon receptor agonist (1:1 ratio) for weight loss and fatty liver disease (MASH/MASLD). The human evidence is unusually solid: trials show substantial liver fat reduction and meaningful weight loss, with tolerability varying by trial and dose. Antifibrotic benefit and long-term durability are still preliminary, based on limited Phase 2 data. GI side effects are the main risk, and it is not yet FDA-approved.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Pemvidutide is a novel investigational peptide developed by Altimmune that functions as a balanced 1:1 glucagon/GLP-1 dual receptor agonist. Unlike GLP-1/GIP agonists (such as tirzepatide), pemvidutide combines GLP-1 activity with glucagon receptor activation in equal measure, which is believed to directly target liver fat through enhanced fatty acid oxidation while also reducing appetite and body weight. This dual mechanism makes pemvidutide particularly suited for MASH (metabolic dysfunction-associated steatohepatitis), a serious liver disease closely linked to obesity.
In the IMPACT Phase 2b trial (n=212, 48 weeks) in patients with biopsy-confirmed MASH and fibrosis stages F2/F3, pemvidutide achieved statistically significant improvements in key non-invasive markers of liver fibrosis and inflammation. The higher of the two doses tested achieved 7.5% weight loss (vs 0.2% placebo) at 48 weeks with no plateau, alongside 54.7% reduction in liver fat content, substantial reductions in ELF score (-0.58 vs +0.16 placebo) and liver stiffness (-3.97 kPa vs -0.03 placebo). The adverse event discontinuation rate was lower than placebo (1.2% vs 3.5%).
In a separate 24-week MASLD trial, one of the doses tested achieved a 75.2% relative reduction in liver fat content, with 84.6% of participants achieving 50% or greater liver fat reduction and 53.8% achieving liver fat normalization. Altimmune has completed a productive End-of-Phase 2 meeting with the FDA and has initiated PERFORMA, its registrational Phase 3 MASH trial.
How it works in the body
A balanced 1:1 dual GLP-1/glucagon receptor agonist. The GLP-1 component reduces appetite and improves insulin sensitivity, while the glucagon component activates hepatic lipid oxidation and thermogenesis. This balanced ratio specifically targets liver fat accumulation (MASH/NAFLD) in addition to weight loss.
Research overview
Pemvidutide is being developed by Altimmune (Nasdaq: ALT) as a once-weekly subcutaneous injection. The clinical program has focused on two key areas: MASH/liver disease and obesity. The IMPACT Phase 2b trial (NCT05989711) was a randomized, placebo-controlled, double-blind study enrolling 212 participants with biopsy-confirmed MASH and fibrosis stages F2 or F3, randomized 1:2:2 to 1.2 mg, 1.8 mg, or placebo for 48 weeks. At 24 weeks, MASH resolution improved significantly; biopsy fibrosis improvement did not. At 48 weeks, statistically significant improvements were seen in ELF, LSM, liver fat, ALT, and cT1 vs placebo. The MASLD extension study (Browne et al., JHEP Reports 2025) enrolled 64 participants with MASLD in a 24-week RCT at 1.2, 1.8, and 2.4 mg, showing liver fat reductions of 56.3-76.4% vs 14.0% placebo, with 6.2% body weight loss at 1.8 mg. Earlier Phase 2 obesity data showed pemvidutide achieved weight loss in adults with overweight/obesity. The Lancet published a commentary on pemvidutide's dual mechanism in MASH (2025). Altimmune has completed an End-of-Phase 2 meeting with FDA and has initiated PERFORMA Phase 3 for MASH; FDA was open to incorporating AIM-MASH AI Assist for histologic assessment standardization.
Who researches Pemvidutide?
Commonly researched by
People researching weight management options
Studied for effects on body composition, appetite regulation, or metabolic rate.
People researching blood sugar regulation
Studied for effects on insulin sensitivity, glucose metabolism, or glycemic control.
Important considerations for
Those with Personal/family history of MTC
AbsoluteDual GLP-1/glucagon agonist carries thyroid C-cell tumor risk from GLP-1 component.
Those with History of pancreatitis
HighGLP-1 class effect on pancreatitis risk.
Those with Severe gastroparesis
HighGLP-1 component slows gastric emptying.
Those who are pregnant or breastfeeding
AbsoluteInvestigational — no reproductive safety data.
Safety & interactions
Do not use if
Personal/family history of MTC
AbsoluteDual GLP-1/glucagon agonist carries thyroid C-cell tumor risk from GLP-1 component.
History of pancreatitis
HighGLP-1 class effect on pancreatitis risk.
Severe gastroparesis
HighGLP-1 component slows gastric emptying.
General cautions
Pregnancy
AbsoluteInvestigational — no reproductive safety data.
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(3)
Rated by level of concern
Gastrointestinal adverse events (GLP-1 class effect)
HighPMID 41113119 / PMC12529369; PMID 41237796
Glucagon-mediated effects on blood glucose
LowPMID 41113119 / PMC12529369; PMID 41237796
Limited Phase 3 data
HighClinicalTrials.gov: NCT05989711, NCT06987513, NCT07009860
Interaction summary(8)
Rated by direction with this peptide
Insulin and sulfonylureas
CautionModerateGLP-1 receptor agonism plus weight loss lowers insulin requirements, so co-administered insulin or secretagogues can precipitate hypoglycemia and generally need proactive dose reduction — a well-established class effect, though not specifically characterized for pemvidutide.
GLP-1 RA class labeling (FDA); PMID 41113119
Orally administered drugs generally (delayed gastric emptying)
CautionLowGLP-1 agonists slow gastric emptying and can alter oral drug absorption rate; a dedicated phase 1 DDI study of pemvidutide with metformin, warfarin, atorvastatin, digoxin and a combined oral contraceptive was conducted specifically to size this effect (interventions verified on the registry).
ClinicalTrials.gov NCT04972396
Warfarin
CautionLowNarrow-therapeutic-index anticoagulant whose PK was formally evaluated alongside pemvidutide in the phase 1 DDI study; INR monitoring is prudent when starting or escalating, though no clinically significant interaction has been reported.
ClinicalTrials.gov NCT04972396
Combined oral contraceptives
CautionTheoreticalEthinylestradiol/levonorgestrel exposure was assessed in the pemvidutide DDI study because delayed gastric emptying and GI adverse events (vomiting) could theoretically reduce contraceptive absorption; no efficacy failure has been demonstrated.
ClinicalTrials.gov NCT04972396
Other GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide)
CautionModerateConcurrent use duplicates GLP-1 receptor agonism with no added benefit and additive GI toxicity and hypoglycemia risk; incretin agents are not co-prescribed as a class rule.
GLP-1 RA class labeling (FDA)
Alcohol
CautionLowAlcohol independently drives steatohepatitis and would confound the hepatic benefit; pemvidutide is itself being studied in alcohol use disorder (RECLAIM) and alcohol-associated liver disease (RESTORE), so its interaction with alcohol is an open research question rather than a settled or characterized safety finding — severity kept Low to reflect that no human interaction data exist.
ClinicalTrials.gov NCT06987513, NCT07009860
Resmetirom (THR-beta agonist)
SynergisticTheoreticalMechanistically complementary for MASH — hepatic thyroid-hormone-receptor-beta lipid oxidation versus systemic GLP-1/glucagon action — but no combination trial has been run and the synergy is entirely inferred.
Mechanism-only; no combination trial registered
Antihypertensives
CautionLowPemvidutide lowered blood pressure alongside weight in pooled/meta-analysis data, so additive hypotension is plausible in patients on existing antihypertensive regimens.
PMID 41879841 (GRADE meta-analysis reporting blood pressure reduction)
Known risks(3)
Gastrointestinal adverse events (GLP-1 class effect)
MildStandard GLP-1 class GI effects (nausea, diarrhea) are expected but were notably mild in IMPACT. Discontinuation rates for AEs were lower than placebo.
Glucagon-mediated effects on blood glucose
Mild / Requires MonitoringGlucagon receptor activation can raise blood glucose. Pemvidutide's balanced 1:1 ratio is designed to avoid this, and clinical data showed improvements in metabolic parameters, but monitoring is appropriate especially in diabetic patients.
Limited Phase 3 data
PERFORMA Phase 3 is underway; confirmatory results remain pending. Larger, longer studies may reveal additional safety signals.
Drug interactions(3)
Insulin and insulin secretagogues
The GLP-1 component enhances insulin secretion; co-administration with insulin or sulfonylureas may increase hypoglycemia risk. The glucagon component may partially offset this.
Other GLP-1 or incretin-based therapies
Co-administration not recommended due to overlapping GLP-1 mechanisms. Additive GI effects and appetite suppression possible.
Oral medications with narrow therapeutic index (warfarin, levothyroxine)
GLP-1-mediated gastric emptying delay may alter absorption of co-administered oral drugs.
Research & benefits
Evidence base
- Evidence Level
- Moderate-Strong Evidence
- Total Studies
- 8
Pemvidutide has Phase 2b data in MASH (n=212, 48 weeks) and Phase 2 data in MASLD (n=64, 24 weeks), both demonstrating significant efficacy on liver endpoints and weight loss. FDA End-of-Phase 2 meeting completed with alignment on Phase 3 design. The PERFORMA Phase 3 registrational trial is underway.
Researched for(6)
Rated by confidence in the evidence
Improved non-invasive fibrosis markers in MASH; biopsy-confirmed antifibrotic benefit remains unproven.
LowBiopsy fibrosis endpoint was negative, leaving only surrogate marker evidence, still preliminary.
PMID 41237796 (Noureddin et al., Lancet 2025, IMPACT 24-wk); PMID 41879841 (GRADE meta-analysis, ELF MD -0.44); NCT05989711
Dramatic liver fat reduction (54.7% at 1.8 mg in MASH; 75.2% in MASLD at 24 weeks)
HighConfirmed in a randomized 24-week trial, with up to 75% relative liver fat reduction vs placebo.
PMID 41113119 / PMC12529369 (Browne et al., JHEP Rep 2025, NCT05292911); PMID 39002641 (Harrison et al., J Hepatol)
Clinically meaningful weight loss (up to 7.5% vs 0.2% placebo at 48 weeks in MASH)
HighHuman RCT data show significant body weight reduction, up to 6.2% at 24 weeks vs placebo.
PMID 41113119 / PMC12529369; NCT04561245; NCT05989711
Outstanding tolerability — lower discontinuation rate than placebo (1.2% vs 3.5%)
MediumDiscontinuation due to adverse events was low in IMPACT but higher than placebo in the higher-dose MOMENTUM groups.
PMID 41237796 (Lancet, IMPACT); PMID 41113119 / PMC12529369 (JHEP Rep)
No weight loss plateau observed at 48 weeks with 1.8 mg dose
SpeculativeSingle unpublished trial readout suggests continued weight loss at 48 weeks without plateau.
NCT05989711 (48-wk results not published at time of check)
Liver fat normalization in majority of MASLD patients (53.8% achieved <=5% liver fat at 1.8 mg)
HighRandomized trial found over half of patients reached normal liver fat levels at 1.8 mg.
PMID 41113119 / PMC12529369 (Browne et al., JHEP Rep 2025, NCT05292911)
Benefits(6)
Improved non-invasive fibrosis markers in MASH; biopsy-confirmed antifibrotic benefit remains unproven.
IMPACT Phase 2b (NCT05989711, n=212, 48 weeks, Altimmune Dec 2025)
Dramatic liver fat reduction (54.7% at 1.8 mg in MASH; 75.2% in MASLD at 24 weeks)
IMPACT Phase 2b and MASLD trial (Browne et al., JHEP Reports 2025)
Clinically meaningful weight loss (up to 7.5% vs 0.2% placebo at 48 weeks in MASH)
IMPACT Phase 2b at 48 weeks
Outstanding tolerability — lower discontinuation rate than placebo (1.2% vs 3.5%)
IMPACT Phase 2b — no serious or severe treatment-related AEs
No weight loss plateau observed at 48 weeks with 1.8 mg dose
IMPACT Phase 2b — continued weight loss from 24 to 48 weeks
Liver fat normalization in majority of MASLD patients (53.8% achieved <=5% liver fat at 1.8 mg)
MASLD trial (Browne et al., JHEP Reports 2025, n=64)
Key studies(2)
IMPACT Phase 2b: Pemvidutide in MASH with Fibrosis (48-week results)
Phase 2b RCTn=21248 weeksAltimmune / Noureddin M (PI)
Altimmune press release (December 2025); The Lancet commentary (2025)
2025
Pemvidutide 1.8 mg achieved ELF -0.58 vs +0.16 placebo, LSM -3.97 vs -0.03 placebo, liver fat -54.7% vs -8.2%, ALT -37.4 vs -10.3 IU/L, and 7.5% weight loss vs 0.2% placebo. 32.4% achieved combined ELF and LSM targets vs 3.2% placebo. Discontinuation due to AEs 1.2% vs 3.5% placebo. These were secondary non-invasive measures at 48 weeks; LSM comparisons had p<0.05 and p<0.001. The biopsy fibrosis primary endpoint was not met at 24 weeks.
Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease
Phase 2 RCT (extension)n=6424 weeksBrowne SK, Suschak JJ, Tomah S, Gutierrez JA, et al.
JHEP Reports
2025
Pemvidutide 1.8 mg achieved 75.2% relative liver fat reduction vs 14% placebo (p<0.001). 84.6% achieved >=50% liver fat reduction; 53.8% achieved normalization (<=5% liver fat). Body weight reduced 6.2% (p<0.001 vs placebo). Well tolerated at all doses.
Regulation & availability
Why researchers look at it
Pemvidutide sits at the intersection of obesity and liver disease. Its balanced GLP-1/glucagon mechanism targets liver fat — achieving 75% liver fat reduction in some trials — while also delivering meaningful weight loss, with low discontinuation in IMPACT; tolerability varied across trials.
- Estimated cost
- No approved product or established prescription price; Phase 3 underway.
- FDA status
- Not FDA-approved; pemvidutide is an investigational drug available in the US only through clinical trials, and it is not eligible for compounding. PERFORMA Phase 3 is underway following FDA End-of-Phase 2 feedback on MASH trial design; Altimmune announced its initiation on August 3, 2026. FDA was open to incorporating AIM-MASH AI Assist for histological assessment.
- WADA status
- Prohibited at all times under WADA S0 because pemvidutide has no governmental approval for human therapeutic use. It need not be explicitly named.
- Prescribability
- Pemvidutide is an investigational drug. It is not FDA-approved, and in the US it is available only through clinical trials; it is not eligible for compounding. No — investigational; PERFORMA Phase 3 underway.
- Availability
- Pemvidutide is an investigational drug with no approved prescription product. It has completed Phase 2b trials for MASH, and PERFORMA Phase 3 is underway, with 52-week results anticipated in 2029. Approval timing is unconfirmed.
International status
US
Pemvidutide is an investigational drug. It is not FDA-approved, and in the US it is available only through clinical trials; it is not eligible for compounding.
Worldwide
Investigational — not yet approved anywhere
Regulatory timeline(9)
- 2021Pemvidutide enters Phase 1 clinical development at Altimmune
- 2022Phase 2 obesity trial initiated
- 2023Phase 2 MASLD trial results — significant liver fat reductions
- 2024IMPACT Phase 2b trial (MASH, F2/F3) initiated (NCT05989711, n=212)
- 2025-H1IMPACT met the MASH-resolution endpoint but missed the fibrosis-improvement endpoint.
- 2025-11MASLD 24-week extension results published in JHEP Reports
- 2025-12IMPACT 48-week topline results — significant improvements in all endpoints vs placebo
- 2025-12End-of-Phase 2 meeting with FDA — alignment on Phase 3 design for MASH F2/F3
- 2026-08-03Altimmune announced initiation of PERFORMA, its registrational Phase 3 MASH trial.
Sources & FAQs
Research sources(4)
Frequently asked questions(4)
What makes pemvidutide different from semaglutide or tirzepatide?
Pemvidutide is a balanced 1:1 GLP-1/glucagon dual agonist, meaning it activates both the GLP-1 and glucagon receptors equally. The glucagon component directly targets the liver, promoting fatty acid oxidation and inhibiting lipogenesis. This gives pemvidutide a strong advantage for liver disease (MASH/MASLD) compared to GLP-1-only drugs.
Is pemvidutide being developed for obesity or liver disease?
Primarily for MASH (liver disease) based on the Phase 2b IMPACT trial. However, it also produces meaningful weight loss (7.5% in MASH patients at 48 weeks). The Phase 3 program will focus on MASH with advanced fibrosis as the initial indication.
How is pemvidutide administered?
Pemvidutide is a subcutaneous injection, similar to semaglutide (Ozempic/Wegovy).
How well tolerated is pemvidutide?
Extremely well tolerated. In the IMPACT Phase 2b trial, the discontinuation rate due to adverse events was actually lower for pemvidutide (0-1.2%) than for placebo (3.5%). No serious or severe treatment-related AEs were reported.